Oral Ivermectin should be considered as a Magic Therapy for Scabies with 98% Cure


Oral Ivermectin should be considered as a Magic Therapy for Scabies with 98% Cure


1Professor Khalifa E. Sharquie MD, PhD, FRCP Edin, 2Professor Adil A. Noaimi MD, DDV, FICMS, 3Dr. Riyam A. Flayyih MD.

1Department of Dermatology, College of Medicine, University of Baghdad. Iraqi and Arab Board for Dermatology and Venereology, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq. 2Department of Dermatology, College of Medicine, University of Baghdad. Iraqi and Arab Board for Dermatology and Venereology, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq. 3Center of Dermatology; Baghdad Teaching Hospital; Medical City, Baghdad, Iraq.


Background: Scabies is one of the commonest endemic pruritic diseases all over the worldwide. Many topical therapeutic options for scabies are available, but none of them could be accepted by many patients as all of them need covering the whole body by ointment overnight. Accordingly patients are looking for safe oral therapy like many other diseases.

Objective: To assess the effectiveness of oral ivermectin in the treatment of scabies. Patients and Methods: This single, blinded, therapeutic work was conducted in the Center of Dermatology and Venereology, Baghdad Teaching Hospital, Baghdad, Iraq during the period from April 2018 through October 2019. Fifty of patients with scabies were involved in this study. All socio-demographic data that related to the disease were obtained from each patient. History and clinical examination was done for each case to establish   the diagnosis. Fifty patients treated by ivermectin tablet 200 microgram per kg as a single dose on empty stomach and repeated after one week. The patients were seen regularly every 2 weeks for 4 weeks duration after stopping therapy, to re-asses cure and to report any local or systemic side effects.

Results: A total of 50 patients were included in this study, 21 (42%) males and 29 (58%) females. The ages of males ranged from 5-47 with a mean 20.90±13.034 years; while the age range of females ranged from 3-67 (30.69±18.766) years. At the end of four weeks after stopping therapy , the response to treatment was as follows: Response in 49 (98%) patients and no response in 1 (2%) patients. No cutaneous or systemic side effects were noticed in any patients, while the recurrence or relapse rate was documented in 2 (4%) patients.

Conclusion: Oral ivermectin had achieved cure of scabies in 98% of patients, hence it should be considered as a mass treatment in cases of outbreak and epidemics as it is easy to be used with no significant side effects especially when compared with topical agents.


Keywords: Oral Ivermectin, Therapy, Scabies.


Free Full-text PDF


How to cite this article:
Khalifa E. Sharquie, Adil A. Noaimi ,Riyam A. Flayyih. Oral Ivermectin should be considered as a Magic Therapy for Scabies with 98% Cure .American Journal of Dermatological Research and Reviews, 2020, 3:24. DOI: 10.28933/ajodrr-2020-03-2705


References:

1. Currier RW, Walton SF, Currie BJ. Scabies in animals and humans: history, evolutionary perspectives, and modern clinical management. Annals of the New York Academy of Sciences. 2011 Aug; 1230(1):E50-60.
2. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. New England Journal of Medicine. 2010 Feb 25; 362(8):717-25.
3. Scheinfeld N. Controlling scabies in institutional settings. American Journal of clinical dermatology. 2004 Feb 1; 5(1):31-7.
4. Al-Badri AA. Epidemiological and therapeutic study of scabies in Baghdad (Master thesis in Community Medicine, College of Medicine University of Baghdad), 1994
5. Scott GR, Chosidow O; IUSTI/WHO .European guideline for the management of scabies, 2010.Int J STD AIDS. 2011 Jun; 22(6):301-3.
6. Meinking T, Burkhart CG, Burkhart CG, James R. Ectoparasitic diseases in dermatology: reassessment of scabies and pediculosis, pp. 77–108. Advances in dermatology, vol. 15. 1999.
7. Meinking TL, Taplin D, Herminda JL, Pardo R, Kerdel FA. The treatment of scabies with ivermectin. New England Journal of Medicine. 1995 Jul 6; 333(1):26-30.
8. Workowski KA, Bolan GA. sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports. 2015 Jun 5; 64(RR-03):1.
9. Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. The Lancet. 1997; 349(9059):1144-5.
10. Marks M, Taotao-Wini B, Satorara L, Engelman D, Nasi T, Mabey DC, Steer AC. Long term control of scabies fifteen years after an intensive treatment programme. PLoS neglected tropical diseases. 2015 Dec;9(12).
11. Usha V, Nair TG. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. Journal of the American Academy of Dermatology. 2000 Feb 1;42(2):236-40.
12. Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database of Systematic Reviews. 2007(3).
13. Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clinical Infectious Diseases. 2004 Jul 1; 39(1):e8-12.
14. Mounsey KE, Holt DC, McCarthy JS, Currie BJ, Walton SF. Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic communities. Archives of dermatology. 2009 Jul 1; 145(7):840-1.
15. Roos TC, Roos S, Merk HF, Bickers DR. Pharmacotherapy of ectoparasitic infections. Drugs. 2001 Jul 1; 61(8):1067-88.
16. Fuller LC. Epidemiology of scabies. Current opinion in infectious diseases. 2013 Apr 1; 26(2):123-6.
17. Fawcett RS. Ivermectin use in scabies. American family physician. 2003 Sep 15; 68(6):1089-92.
18. Steer AC, Kearns T, Andrews RM, McCarthy JS, Carapetis JR, Currie BJ. Ivermectin worthy of further investigation. Bulletin of the World Health Organization. 2009;87:A-B.
19. Dhana A, Yen H, Okhovat JP, Cho E, Keum N, Khumalo NP. Ivermectin versus permethrin in the treatment of scabies: A systematic review and meta-analysis of randomized controlled trials.
20. Engelman D, Martin DL, Hay RJ, Chosidow O, McCarthy JS, Fuller LC, Steer AC. Opportunities to investigate the effects of ivermectin mass drug administration on scabies. Parasites & vectors. 2013 Dec; 6(1):106.
21. Ichikawa M, Tanaka M, Naritomi Y, Furue M. Combined ivermectin and topical therapy significantly reduces treatment time in aged scabietic patients. The Journal of dermatology. 2013 Apr 5; 4(40):306-7.
22. Sasaki I. What kind of drug is ivermectin? In: Nanko H, ed. Scabies Management Perfect Guide. Tokyo: Shujunsha, 2008; 124–13..
23. Mounsey KE, McCarthy JS. Treatment and control of scabies. Current opinion in infectious diseases. 2013 Apr 1; 26(2):133-9.
24. Brooks PA, Grace RF. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. Journal of paediatrics and child health. 2002 Aug; 38(4):401-4.
25. Alipour H, Goldust M. The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. Annals of parasitology. 2015;61(2):79-84.
26. Sharquie KE, Al-Rawi JR, Noaimi AA, Al-Hassany HM. Treatment of scabies using 8% and 10% topical sulfur ointment in different regimens of application. Journal of drugs in dermatology: JDD. 2012 Mar; 11(3):357-64.
27. Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, Tuicakau M, Koroi A, Andrews RM, Kaldor JM, Steer AC. Mass drug administration for scabies—2 years of follow-up. New England Journal of Medicine. 2019 Jul 11; 381(2):186-7.